Skip to Content

Are you based in North America? If yes, switch to our North American website →

cMYC (MYC) Breakapart

Applications
haematology
Catalogue Numbers
LPH 010-S (5 tests)
LPH 010 (10 tests)

Probe Specification

  • cMYC, 8q24.21, Red
  • cMYC, 8q24.21, Green

The cMYC probe mix consists of a 173kb probe labelled in red, centromeric to the MYC gene that includes the marker D8S1153 and a 186kb probe, labelled in green telomeric to the MYC gene that includes the D8S1644 marker.

Probe Information

Chromosomal rearrangements involving the MYC (MYC proto-oncogene, bHLH transcription factor) gene at 8q24 are recognised recurrent abnormalities commonly seen in patients with B-cell malignancy.

MYC rearrangements, activating MYC by translocation with one of the three immunoglobulin loci (IGH, IGL or IGK), are detected in almost all cases of Burkitt lymphoma at diagnosis1. They are also seen in diffuse large B-cell lymphoma (DLBCL)2, multiple myeloma and plasmablastic lymphomas3,4, amongst other diseases.

MYC has also been shown on rare occasions to be involved in rearrangements with a number of non-immunoglobulin partners5.

The presence of concurrent MYC rearrangements with BCL2 and/or BCL6 rearrangements in patients with ‘dual-hit’ lymphoma has been shown to be associated with aggressive disease6.

I am grateful for the excellent products I receive from Cytocell at a reasonable price, but more importantly the superb customer support.  The speed in which I receive answers or suggestions makes my life as a director much easier and allows me to focus on patient care.  The quality and consistency of Cytocell’s probes means I can trust the results, and my clients get their results in a timely manner. Dr. Theresa C. Brown, Director, Cytogenetics Laboratory, Hayward Genetics Center, Tulane University School of Medicine

References

  1. Perkins AS, Friedberg JW. Hematology Am Soc Hematol Educ Program. 2008;341-8
  2. Ott G, et al., Blood. 2013 Dec 5;122(24):3884-91
  3. Walker BA, et al., Blood Cancer J. 2014;4(3)
  4. Elyamany G, et al., Adv Hematol 2015;2015:315289
  5. Bertrand P, et al., Leukemia 2007;21:515-23
  6. Aukema SM, et al., Blood. 2011; Feb 24;117(8):2319-31
  7. Arsham, MS., Barch, MJ. and Lawce HJ. (eds.) (2017) The AGT Cytogenetics Laboratory Manual. New Jersey: John Wiley & Sons Inc.
  8. Mascarello JT, Hirsch B, Kearney HM, et al. Section E9 of the American College of Medical Genetics technical standards and guidelines: fluorescence in situ hybridization. Genet Med. 2011;13(7):667-675.
  9. Wiktor AE, Dyke DLV, Stupca PJ, Ketterling RP, Thorland EC, Shearer BM, Fink SR, Stockero KJ, Majorowicz JR, Dewald GW. Preclinical validation of fluorescence in situ hybridization assays for clinical practice. Genetics in Medicine. 2006;8(1):16–23.

Microscope Images

CMYC (MYC) Breakapart magnified
Area of Interest*
Lymphoma

Disclaimer

This product is intended to be used on Carnoy’s solution (3:1 methanol/acetic acid) fixed haematological samples.

*Disease information supported by the literature and is not a reflection of the intended purpose of this product.